Piper Sandler analyst David Westenberg lowered the firm’s price target on Myriad Genetics (MYGN) to $14 from $24 and keeps a Neutral rating on the shares. The firm is also updating its Myriad estimates to account for lower pharmacogenomics revenue following the dropping of GeneSight coverage by United Healthcare.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MYGN:
- Myriad Genetics unveils resesrch at SMFM on cfDNA
- Myriad Genetics introduces online prenatal genetic testing resource
- Myriad Genetics announces hereditary cancer risk assessment study published
- Myriad Genetics sees Q4 adjusted EPS 3c-4c, consensus 3c
- Myriad Genetics sees FY24 adjusted EPS 14c-15c, consensus 13c